MedTrace Logo

Combined Haploidentical-Cord Blood Transplantation for Adults and Children

NCT00943800 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2021-01-27

Study results available
· View outcomes & findings →

Summary

The primary objective is to assess the rate of engraftment with combined haploidentical-cord blood transplantation. The secondary objective is to evaluate the incidence and severity of acute and chronic graft-versus-host disease (GVHD).

Conditions

Interventions

DRUG

Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)

Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.

PROCEDURE

Stem Cell Transplant

Infusion of haploidentical donor, umbilical cord blood

PROCEDURE

Stem Cells Collections

Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.

DRUG

Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)

Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.

DRUG

Fludarabine, Busulfan, and ATG

Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Hongtao Liu, M.D. · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-09
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00943800 on ClinicalTrials.gov